MIST SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 20, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Milestone Pharmaceuticals Receives Nasdaq Minimum Bid Price Deficiency Notice

Oct 28, 2026

8-K

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China

Sep 3, 2026

8-K

Milestone Pharmaceuticals Reports Q2 2026 Financial Results and Corporate Updates

Aug 12, 2026

8-K

Milestone Pharmaceuticals Inc. Announces Results of 2026 Annual Meeting of Shareholders

Jun 15, 2026

8-K

Milestone Pharmaceuticals Reports Q1 2026 Financial Results and Provides Corporate Update on CARDAMYST™ Launch

May 13, 2026

8-K

Milestone Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results and Provides Update on CARDAMYST™ Commercial Launch

Mar 20, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Jul 14, 2025

424B5

SHELF OFFERING | | Bank: H.C. Wainwright & Co.

Jul 11, 2025

424B5

ATM | Offering amount: $75,000,000 | Amount sold to date: $2,800,000

Mar 18, 2025

424B5

SHELF OFFERING | Shares amount: 16,666,667 | Share price: $1.50 | Warrants amount: 3,333,333 | Offering amount: $29,996,666.67

Mar 1, 2024

424B5

PENDING OFFERING | PENDING OFFERING | Share price: $2.20

Feb 28, 2024

424B5

ATM | Offering amount: $47,249,368 | Amount sold to date: $2,750,632

May 31, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-3

[No Baby Shelf]* May 2026 SHELF and ATM

May 13, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 12, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 13, 2025

S-3

SHELF | Offering amount: $250,000,000.00 EFFECTIVE

Nov 12, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 12, 2024

S-3

SHARE RESALE REGISTRATION | Shares amount: 13,888,850 | Share price: $4.40 | Conversion price: $5.23 EFFECTIVE

May 15, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jul 15, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jul 15, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

Pavaki Capital Management LLC (Filed by)

Aug 7, 2026

Giles Lisa M. (Reporting)

Jun 12, 2026

Fischer Seth H. Z. (Reporting)

Jun 12, 2026

Duty Stuart (Reporting)

Jun 12, 2026

Wills Robert James (Reporting)

Jun 12, 2026

TOMSICEK MICHAEL JOHN (Reporting)

Jun 12, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 26, 2026

CORRESP

Form CORRESP - Correspondence

May 20, 2026

LETTER

Form UPLOAD - SEC-generated letter

May 18, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 25, 2024

CORRESP

Form CORRESP - Correspondence

Nov 20, 2024

LETTER

Form UPLOAD - SEC-generated letter

Nov 19, 2024

Milestone Pharmaceuticals Inc. MIST · SEC Filings